MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer
MRTX1719 是一种 MTA 协同 PRMT5 抑制剂，在 MTAP 缺失型癌症的临床前模型和患者中表现出合成致死性。
期刊:Cancer Discovery
影响因子:29.7
doi:10.1158/2159-8290.CD-23-0669
Lars D Engstrom ,Ruth Aranda ,Laura Waters ,Krystal Moya ,Vickie Bowcut ,Laura Vegar ,David Trinh ,Allan Hebbert ,Christopher R Smith ,Svitlana Kulyk ,J David Lawson ,Leo He ,Laura D Hover ,Julio Fernandez-Banet ,Jill Hallin ,Darin Vanderpool ,David M Briere ,Alice Blaj ,Matthew A Marx ,Jordi Rodon ,Michael Offin ,Kathryn C Arbour ,Melissa L Johnson ,David J Kwiatkowski ,Pasi A Jänne ,Candace L Haddox ,Kyriakos P Papadopoulos ,Jason T Henry ,Konstantinos Leventakos ,James G Christensen ,Ronald Shazer ,Peter Olson
